LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus
Type 1 diabetes mellitus (T1DM) is characterized by beta cell loss because of an autoimmune attack. Here the authors show that an agonist for LRH-1/NR5A2, a nuclear receptor known to be protective against beta cell apoptosis, inhibits immune-mediated inflammation and hyperglycemia in T1DM mouse mode...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-04-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-03943-0 |
| id |
doaj-fbb9d971aff1451c95b83f3e8763290c |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Nadia Cobo-Vuilleumier Petra I. Lorenzo Noelia García Rodríguez Irene de Gracia Herrera Gómez Esther Fuente-Martin Livia López-Noriega José Manuel Mellado-Gil Silvana-Yanina Romero-Zerbo Mathurin Baquié Christian Claude Lachaud Katja Stifter German Perdomo Marco Bugliani Vincenzo De Tata Domenico Bosco Geraldine Parnaud David Pozo Abdelkrim Hmadcha Javier P. Florido Miguel G. Toscano Peter de Haan Kristina Schoonjans Luis Sánchez Palazón Piero Marchetti Reinhold Schirmbeck Alejandro Martín-Montalvo Paolo Meda Bernat Soria Francisco-Javier Bermúdez-Silva Luc St-Onge Benoit R. Gauthier |
| spellingShingle |
Nadia Cobo-Vuilleumier Petra I. Lorenzo Noelia García Rodríguez Irene de Gracia Herrera Gómez Esther Fuente-Martin Livia López-Noriega José Manuel Mellado-Gil Silvana-Yanina Romero-Zerbo Mathurin Baquié Christian Claude Lachaud Katja Stifter German Perdomo Marco Bugliani Vincenzo De Tata Domenico Bosco Geraldine Parnaud David Pozo Abdelkrim Hmadcha Javier P. Florido Miguel G. Toscano Peter de Haan Kristina Schoonjans Luis Sánchez Palazón Piero Marchetti Reinhold Schirmbeck Alejandro Martín-Montalvo Paolo Meda Bernat Soria Francisco-Javier Bermúdez-Silva Luc St-Onge Benoit R. Gauthier LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus Nature Communications |
| author_facet |
Nadia Cobo-Vuilleumier Petra I. Lorenzo Noelia García Rodríguez Irene de Gracia Herrera Gómez Esther Fuente-Martin Livia López-Noriega José Manuel Mellado-Gil Silvana-Yanina Romero-Zerbo Mathurin Baquié Christian Claude Lachaud Katja Stifter German Perdomo Marco Bugliani Vincenzo De Tata Domenico Bosco Geraldine Parnaud David Pozo Abdelkrim Hmadcha Javier P. Florido Miguel G. Toscano Peter de Haan Kristina Schoonjans Luis Sánchez Palazón Piero Marchetti Reinhold Schirmbeck Alejandro Martín-Montalvo Paolo Meda Bernat Soria Francisco-Javier Bermúdez-Silva Luc St-Onge Benoit R. Gauthier |
| author_sort |
Nadia Cobo-Vuilleumier |
| title |
LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus |
| title_short |
LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus |
| title_full |
LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus |
| title_fullStr |
LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus |
| title_full_unstemmed |
LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus |
| title_sort |
lrh-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2018-04-01 |
| description |
Type 1 diabetes mellitus (T1DM) is characterized by beta cell loss because of an autoimmune attack. Here the authors show that an agonist for LRH-1/NR5A2, a nuclear receptor known to be protective against beta cell apoptosis, inhibits immune-mediated inflammation and hyperglycemia in T1DM mouse models. |
| url |
https://doi.org/10.1038/s41467-018-03943-0 |
| work_keys_str_mv |
AT nadiacobovuilleumier lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT petrailorenzo lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT noeliagarciarodriguez lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT irenedegraciaherreragomez lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT estherfuentemartin lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT livialopeznoriega lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT josemanuelmelladogil lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT silvanayaninaromerozerbo lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT mathurinbaquie lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT christianclaudelachaud lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT katjastifter lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT germanperdomo lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT marcobugliani lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT vincenzodetata lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT domenicobosco lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT geraldineparnaud lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT davidpozo lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT abdelkrimhmadcha lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT javierpflorido lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT miguelgtoscano lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT peterdehaan lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT kristinaschoonjans lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT luissanchezpalazon lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT pieromarchetti lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT reinholdschirmbeck lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT alejandromartinmontalvo lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT paolomeda lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT bernatsoria lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT franciscojavierbermudezsilva lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT lucstonge lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus AT benoitrgauthier lrh1agonismfavoursanimmuneisletdialoguewhichprotectsagainstdiabetesmellitus |
| _version_ |
1721449717510963200 |
| spelling |
doaj-fbb9d971aff1451c95b83f3e8763290c2021-05-11T09:35:00ZengNature Publishing GroupNature Communications2041-17232018-04-019111510.1038/s41467-018-03943-0LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitusNadia Cobo-Vuilleumier0Petra I. Lorenzo1Noelia García Rodríguez2Irene de Gracia Herrera Gómez3Esther Fuente-Martin4Livia López-Noriega5José Manuel Mellado-Gil6Silvana-Yanina Romero-Zerbo7Mathurin Baquié8Christian Claude Lachaud9Katja Stifter10German Perdomo11Marco Bugliani12Vincenzo De Tata13Domenico Bosco14Geraldine Parnaud15David Pozo16Abdelkrim Hmadcha17Javier P. Florido18Miguel G. Toscano19Peter de Haan20Kristina Schoonjans21Luis Sánchez Palazón22Piero Marchetti23Reinhold Schirmbeck24Alejandro Martín-Montalvo25Paolo Meda26Bernat Soria27Francisco-Javier Bermúdez-Silva28Luc St-OngeBenoit R. Gauthier29Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICUnidad de Gestión Clínica Intercentros de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de MálagaNeurix SADepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICUlm University HospitalFacultad de Ciencias de la Salud, Universidad de BurgosDepartment Clinical and Experimental Medicine, University of Pisa—AOUP University HospitalDepartment of Translational Research and of New Surgical and Medical Technologies, University of PisaCell Isolation and Transplantation Centre, University HospitalCell Isolation and Transplantation Centre, University HospitalDepartment of Cell Dynamics and Signalling, CABIMER-Andalusian Center for Molecular Biology and Regenerative MedicineDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICClinical Bioinformatics Area, Fundación Progreso y Salud, Consejería de SaludAmarna TherapeuticsAmarna TherapeuticsLaboratory of Metabolic Signaling, EPFLBiological Resources, CABIMER-Andalusian Center for Molecular Biology and Regenerative MedicineDepartment Clinical and Experimental Medicine, University of Pisa—AOUP University HospitalUlm University HospitalDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICDepartment of Cell Physiology and Metabolism, University of GenevaDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICUnidad de Gestión Clínica Intercentros de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de MálagaDepartment of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSICType 1 diabetes mellitus (T1DM) is characterized by beta cell loss because of an autoimmune attack. Here the authors show that an agonist for LRH-1/NR5A2, a nuclear receptor known to be protective against beta cell apoptosis, inhibits immune-mediated inflammation and hyperglycemia in T1DM mouse models.https://doi.org/10.1038/s41467-018-03943-0 |